Almac Discovery
Almac Discovery is an innovative biotech company operating within and supported by the Almac Group of companies. It is led by an experienced team (ex Pharma and Biotech), with a track record in delivering successful clinical stage programmes. Almac Discovery utilises its capabilities and expertise to discover and develop novel first-in-class/best-in-class NCEs and Novel Protein Therapeutics through to IND-ready stage, after which it seeks to collaborate with partners to continue into clinical development.
Its core expertise and arising portfolio are focussed on two areas:
a) Targeting the Deubiquitinating enzyme class (DUBs) linked to protein homeostasis and degradation through the application of its proprietary Ubi-Plex technology platform, and,
b) Next Generation Protein:Drug Conjugate (PDC) technology platform utilising minimal antigen-binding domains combined with Almac's novel, proprietary linker and payload technology.
Drug programmes derived from these platforms are currently being prosecuted both in house and with external collaborators.
Dr Alan Lamont
VP Business Development and Licensing
Almac Group
Almac Pharma Services are the Drug Product Experts within the Almac Group, offering formulation development & GMP Manufacturing services for small molecule, solid oral dose products for both clinical and commercial supply, as well as commercial packaging of all types of dosage forms, for worldwide release and distribution.
Rory Davidson
Business Development Manager – EU
Manuel Figueiredo
Business Development Manager
